Assignee
GRACEWAY PHARMACEUTICALS LLC
US·6 granted patents·6 pending applications·67 citations·filing 2004–2011
Top patents by PatentIndex Score
12 records- 0192US7696159B2Treatment for basal cell carcinomaGRACEWAY PHARMACEUTICALS LLC·Filed 2008·Granted Apr 13, 2010·61 cites·26 claims
- 0281US7335773B2Intermediates for imidazonaphthyridinesGRACEWAY PHARMACEUTICALS LLC·Filed 2006·Granted Feb 26, 2008·2 cites·1 claims
- 0378US7964612B2Therapeutic pyrazolyl thienopyridinesGRACEWAY PHARMACEUTICALS LLC·Filed 2007·Granted Jun 21, 2011·2 cites·12 claims
- 0468US2011021555A1Lower dosage strength imiquimod formulations and shorter dosing regimens for treating actinic keratosesGRACEWAY PHARMACEUTICALS LLC·Filed 2009·Application pending·0 cites
- 0560US7615230B2Method for decreasing sebum productionGRACEWAY PHARMACEUTICALS LLC·Filed 2004·Granted Nov 10, 2009·2 cites·3 claims
- 0657US2011263636A13 x 3 x 3 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMODGRACEWAY PHARMACEUTICALS LLC·Filed 2011·Application pending·0 cites
- 0757US2011263637A1Up to six weeks dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimodGRACEWAY PHARMACEUTICALS LLC·Filed 2011·Application pending·0 cites
- 0853US2011207766A1Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal wartsGRACEWAY PHARMACEUTICALS LLC·Filed 2010·Application pending·0 cites
- 0953US2010197722A1Treatment for basal cell carcinomaGRACEWAY PHARMACEUTICALS LLC·Filed 2010·Application pending·0 cites
- 1050US7981936B2Crystalline ACAT inhibitorGRACEWAY PHARMACEUTICALS LLC·Filed 2009·Granted Jul 19, 2011·0 cites·19 claims
- 1142US7622610B2Crystalline ACAT inhibitorGRACEWAY PHARMACEUTICALS LLC·Filed 2006·Granted Nov 24, 2009·0 cites·10 claims
- 1237US2010092401A1Immune response modifier formulationsGRACEWAY PHARMACEUTICALS LLC·Filed 2007·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →